Arcus Biosciences

NCT03629756

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

NCT03628677

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

NCT03719326

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

NCT03677973

A Study to Investigate the Safety of AB680 in Healthy Volunteers

NCT03720678

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

NCT03846310

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

NCT04087018

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

NCT04104672

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

NCT04575311

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

NCT04772989

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT05154136

A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants

NCT05117554

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

NCT05277012

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

NCT05411146

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

NCT05536141

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT05999513

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

NCT05891171

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT06004921

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

NCT04892875

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

NCT06120075

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

NCT06191796

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

NCT06919991

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)